Can Bristol-Myers Squibb’s Bold Pricing Strategy Reverse Its Fortunes?

Pharmaceutical giant Bristol-Myers Squibb is navigating turbulent waters as it implements an unconventional approach to maintain its market position. With crucial blockbuster drug patents expiring, the company has embarked on an aggressive discounting campaign, offering price reductions of up to 80% directly to patients. This dramatic move raises questions about whether it can effectively counter the downward pressure on its stock performance.

The pharmaceutical landscape presents significant challenges for Bristol-Myers Squibb as key patents near expiration, opening the door to increased generic competition and revenue pressure. In response, the company is taking extraordinary measures through its “BMS Patient Connect” platform. Beginning January 2026, the psoriasis treatment Sotyktu will be available at more than 80% off the standard price. This follows substantial discounts already in... Read more...